Johnson & Johnson's Ethicon division received clearance from the FDA for an expanded indication of its Evarrest patch, which can now be used to help control bleeding during adult liver surgery.
Fierce 15 member Infraredx backed out of its planned $56 million IPO, citing "unfavorable market conditions."
Earlier this year, four new studies showed that stent retrieval devices to physically remove blood clots in the brain can save stroke patients' lives.
U.S. health insurers are joining a swelling chorus of discontent over power morcellators, limiting the products or considering new restrictions a year after the FDA warned against using the devices in certain gynecological procedures.
Medtronic agreed to pay $4.4 million to settle a Department of Justice lawsuit claiming that the company mislabeled imported devices as made in the USA so that it could sell them to the U.S. military.
Medtronic snatched up artificial pancreas technology from Israel-based DreaMed Diabetes for its insulin pumps, the company's latest deal as it looks to diversify its diabetes offerings and cash in on a growing market.
Big med tech companies have been making big moves to transform themselves this year. These changes will undoubtedly make our 2015 top med tech revenue list look substantially different from this one.
Lux Capital, a 15-year-old investment firm, raised $350 million for a new venture fund targeted at science and healthcare startups like devicemakers 3Scan and SOLS, the company said in a blog.
The FDA has agreed to investigate Bayer's Essure birth control device, following complaints of fraud during the clinical trial and dangerous side effects.
Royal Philips is working to get its manufacturing of computed tomography (CT) systems back up and running. It recently said it would resume shipments of CT systems from its Cleveland, OH, facility--but now the FDA has issued a class 2 recall for CT systems from that same location.
Med tech company executives often talk about the need to provide not just products but "solutions" to problems like meeting Affordable Care Act metrics at hospitals and lowering the cost of patient care. Now, Medtronic is expanding its push into healthcare services to a new front with the acquisition of the Netherlands' diabetes and research clinic Diabeter.
An Israeli scientist is developing a system to close wounds and surgical incisions via laser beam.
Boston Scientific added to an existing strength in endoscopy by acquiring Xlumena for up to $75 million plus undisclosed sales milestones.
In the device world, "Symplicity" is synonymous with complexity and spectacular failure, after the surprising and miserable results from Medtronic's Symplicity HTN-3 clinical trial of its (supposedly) hypertension lowering renal denervation device. Despite the setback, the company is trying again.
Roche is touting results from a new study that shows its fetal blood test for Down syndrome works better than traditional screening tests in younger, low-risk pregnant women, a potential boon for the company as it looks to gain ground in a fiercely competitive prenatal testing market.
Jacoti is kicking off the launch of its smartphone-enabled hearing aid, ListenApp. It modifies the sound using software installed into an iPhone.
Alexis Lukianov has resigned as CEO of minimally invasive surgical spine player NuVasive due to violations of the company's expense reimbursement and personnel policies. The amounts involved are said to be immaterial to the company's financial results. The allegations are a result of an independent investigation that was overseen by the NuVasive board.
An app compatible with Apple's HealthKit launched a pilot program with New York City's Icahn School of Medicine at Mount Sinai, in attempt to help patients self-manage COPD.
The latest CE-marked peritoneal dialysis system from Baxter has two-way connectivity that enables healthcare providers to monitor home treatments and adjust them remotely as necessary. The system, called HomeChoice Claria with ShareSource, is expected to reduce manual data input by patients and clinics.
Orthofix has secured an 18-month option to buy eNeura with a $15 million loan. The financing is designed to support the commercialization of the startup's Spring TMS device that FDA cleared last May and is the first portable device available in the U.S. to treat acute pain associated with migraine headache with aura, according to the company.